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Effects of acetate dialysate on transforming growth factor /3k, interleu-
kin, and 1.32-microglobulin plasma levels. To evaluate potential adverse
effects of acetate use in hemodialysis (HD), we measured plasma
interleukin (IL-la, IL-1f3, IL-6), TNFa, TGF31, and /32-microglobulin
levels with ELISA assays in normal (N = 9), CRF (N = 6), CAPD (N
= 7) and HD (N = 8) subjects and compared the effects of acetate (Ac)
and acetate-free (Ac-free) dialysate. TGF/31 was the only cytokine
consistently detected. Compared to normals (median 57, range 53 to 68
pg/mi, one undetected; N = 8), TGF/31 was higher in the CRF (75, 70 to
97 pg/mI, one undetected) and CAPD (75.5, 66 to 116 pg/mI, N = 6)
groups (P < 0.05), and was somewhat higher in the HD (68, 52 to 88
pg/mi) group (P < 0.10). Acutely, TGF/31 pre-HD (70, 63 to 88 pg/mi)
increased above normais post AcHD [79.5, 65 to 140 pg/mI uncorrected
for ultrafiltration (IJF)I and was higher after AcHD versus Ac-free HD
both uncorrected (79.5, 65 to 140 pg/mI vs. 70, 52 to 86 pg/mi) and
corrected for UF (68, 51 to 115 pg/mI vs. 57, 43 to 69 pg/mI; P < 0.05).
/32-microglobulin was not different after AcHD (81.2 8.0 mg/mI)
versus Ac-free HD (72.5 6.9 mg/mI). Signifcantly lower serum
inorganic phosphorus was also found four hours post-AcHD compared
to four hours post-Ac-free HD (0.87 mmol 0.10 SEM vs. 1.05 mmol
0.07 SEM; P < 0.05). Inflammatory cytokines may, therefore, not be
detectable with standard ELISA assays even after HD. TGF/31, which
stimulates extracellular matrix and collagen synthesis and modulates
other cytokines, could affect the progression of CRF and combined with
acetate's possible effects on phosphate kinetics, could play a role in
ectopic calcifications and renal bone disease. Finally, no effect of
acetate on j32-microglobuiin levels was found.
Sodium acetate has been used as a substitute for sodium
bicarbonate in dialysis fluids since 1964 [1]. The usual "bicar-
bonate dialysis" now used in many centers to ameliorate the
syndrome of nausea, vomiting, headache, post-dialysis wash-
out", and hypotension associated with the use of 35 to 45 mmol
acetate also employs 2 to 4 mmol acetic acid to prevent calcium
precipitation in the dialysate, and thus still exposes patients to
acetate well beyond physiologic levels [2].
Acetate may also contribute to the long-term chronic com-
plications of dialysis. Interleukin 1 (IL-l) and tumor necrosis
factor (TNF), produced by activated monocytes, are both
reported to be elevated in hemodialysis patients [3—51, and both
increase fibroblast proliferation [6] and osteoclast activity [7—81.
In vitro studies have implicated acetate as one cause of this
activation [9]. Acetate and its metabolism are also reported to
cause: 1) intracellular movement and precipitation of inorganic
phosphorus [2, 10]; 2) alterations of glucose and lipid metabo-
lism; and 3) uncoupling of oxidative phosphorylation and hy-
poxemia [2].
Combined, these potential effects of the chronic use of
acetate might have adverse consequences in the form of in-
creased atherogenesis, vascular calcification, and altered bone
metabolism. Acetate's effects on other cytokines that are in-
volved in these processes have not been studied. Platelet-
derived growth factor (PDGF) has a significant role in the
pathogenesis of atherosclerosis [11] and is reported to be
elevated by an unknown mechanism during hemodialysis [12].
Transforming growth factor beta (TGF/3), a platelet and bone
derived cytokine with many actions [131, including the stimu-
lation of extracellular matrix synthesis [14—17], modulation of
other cytokines such as IL-1/3 [13, 181 and PDGF [19], and
regulation of new bone formation [13, 20], has yet to be
measured in dialysis patients. Although not a cytokine, f2-
microglobulin amyloid deposition occurs in joint capsules,
carpal tunnel structures, tendons, and bone [21]. Since mono-
cytes that are activated in vitro by osmolar changes, gamma
interferon, and TNF, release /32-microglobulin [22], it is possi-
ble acetate could also result in increased p2-microglobulin
synthesis or release.
This study was designed to determine the effect, if any, of
acetate on IL-la, IL-1$, TNFa, PDGF, TGFI3 and 132-micro-
globulin levels during hemodialysis. Normal subjects, non-
dialyzed uremics, and CAPD patients served to control for the
effects of uremia per se on these levels.
Methods
The protocol for this study was approved by the Human
Subjects Committee of the Johns Hopkins University School of
Medicine (JHU). All subjects were fully informed of the nature
of the study and volunteered to participate.
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Subject groups
Four groups were studied: a reference group drawn from the
medical staff of JHU with no history of renal disease or other
chronic illnesses (Normal). non-dialyzed chronic renal failure
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Table 1. Clinical characteristics of the groups
Age
years
Sex
male.female
Race
Black: White
Etiology of renal
failure
Normals 40 3 6:3 1:8 —
(N =9)
CRF 44 6 2:4 3:3 Glomerulonephritis 2(N = 6) Renovascular
Pyelonephritis
Unknown
2
I
1
CAPD 52 7 4:3 4:3 Glomerulonephritis 3(N = 7) Interstitial
nephritis
Polycystic
Hypertensive
2
I
I
HD 49 5 4:4 6:2 Glomerulonephritis 4(N = 8) Pyelonephritis
Polycystic
Obstruction
Unknown
I
1
I
I
patients (CRF); chronic ambulatory peritoneal dialysis patients
(CAPD); hemodialyzed chronic renal failure patients known to
tolerate three times per week hemodialysis with 40 mmol
acetate dialysate (HD).
Clinical characteristics of the groups are shown in Table 1.
The mean prior durations of dialysis treatments were 54.7
months 5.1 SEM and 41.1 months 12.5 SEM for HD and
CAPD patients, respectively.
Study design
All subjects in each group had blood sampled once, except
for hemodialysis patients who were studied over a two week
period: one week with the use of 41 mmol acetate dialysate, and
one week with 39 mmol bicarbonate dialysate acidified with
hydrochloric rather than acetic acid to prevent calcium precip-
itation (acetate-free dialysate). The limited availability of ace-
tate-free dialysate required that four HD subjects be treated
first with acetate followed by acetate-free, and the other four
HD subjects treated with acetate-free followed by acetate.
Dialysate compositions are given in Table 2. The acetate-free
dialysate was formulated to match the composition of the
commercial acetate dialysate (Erilyte 8332, National Medical
Care, USA) in use in the dialysis unit. CAPD subjects all used
a commercial dialysate (Dianeal PD2, Baxter Health Care,
USA). Blood was sampled at the beginning and end of the first
dialysis of the week on each dialysate and at the beginning of
the first HD of the third week. Each dialysis was four hours in
duration. Unmodified Travenol SPS machines (Model 450) 250
mi/mm blood flows, 500 mI/mm dialysate flows, and SCE 135
hollow fiber dialyzers (CD Medical, USA) were used.
Routine laboratory tests
Platelet counts were performed with standard instrumenta-
tion (Coulter S plus 4). Serum sodium, potassium, chloride,
bicarbonate, urea nitrogen, creatinine, glucose, magnesium,
calcium, phosphate, albumin, aspartate amino transferase
(AST), and alkaline phosphatase were measured with a multi-
channel analyzer (Hitachi Model 737). Serum acetate was
measured by the method of Gwynn and Veech [231.
Table 2. Dialysate composition (mmol/Iiter)
Acetate Acetate free Peritoneal
Sodium 140 140 132
Potassium 2.0 2.0 0
Chloride 106 108 96
Bicarbonate 0 39 0
Magnesium .75 .75 .25
Calcium 1.75 1.75 1.75
Acetate 41 0 0
Lactate 0 0 40
Glucose 5.5 5.5 8.3
Plasma cytokine and f32-micro globulin assay
Blood was drawn into 10 cc Thrombotect Vacutainer tubes
(Abbott, North Chicago, Illinois, USA), cooled on ice, centri-
fuged at 1000 g for 15 minutes at 4°C. Plasma was pipetted then
centrifuged at 15,000 g for 20 minutes at 4°C to remove
platelets. The 1.5 ml aliquots were frozen at —70°C in NUNC
tubes then thawed for assay.
All assays were performed in duplicate. TNF was measured
on 50 d/aliquots with a commercial ELISA kit (T-Cell Science,
Cambridge, Massachusetts, USA). The assay had a detection
limit (DL) of 10 pg/mi. IL-la was measured on 100 d aliquots
with a commercial ELISA kit (Endogen, Boston, Massachu-
setts, USA; DL 50 pg/mI). IL-1/3 was measured with a commer-
cial ELISA kit (Cistron Biotechnology, Pine Brooks, New
Jersey, USA; DL 20 pg/mI). IL-6 was measured by a commer-
cial ELISA kit (R&D System, Minneapolis, Minnesota, USA;
DL 20 pg/mi). Interferon gamma (IFNy) was measured using a
commercial ELISA kit (AMGEN, Thousand Oaks, California,
USA; DL 5 U/mI). TGF/31 was measured on 200 d aliquots of
acid ethanol extracted and dialyzed plasma by an ELISA assay
according to the Danielpour method [241 using antibodies which
were a gift of Dr. Michael Sporn (Laboratory of Chemopreven-
tion, NCI, Bethesda, Maryland, USA; DL 50 pg/mI). Platelet
factor 4 (PF4) and /3-thromboglobulin (/3-TG) were measured as
markers of platelet activation [25] using commercial RIA kits
(Abbott Laboratory, and Amersham Corp., Arlington Heights,
Illinois, USA, respectively). f32-microglobulin was measured in
30 uI aliquots (diluted 1:10 to 1:400; DL 20 ng/ml) using a
commercial ELISA kit (Beta-2 M-trac, INCSTAR, Stillwater,
Minnesota, USA). Post-HD cytokine and f32-microglobulin lev-
els were corrected for ultrafiltration by the formula of Berg-
strOm and Wenle [26].
Statistical analysis
Kruskal-Wallis non-parametric analysis of variance was used
for comparison between groups, and the Wilcoxon rank sum
test for differences between pre- and post-HD values. P < 0.05
was considered significant. Data are expressed as mean SEM
or as median plus range if values below the detection limit of the
assay were obtained for any subjects in the group.
Results
Chemistries
Results for the normal, CRF, and CAPD groups and the HD
group's predialysis values are shown in Table 3. As expected,
blood urea nitrogens, creatinines, and bicarbonates were signif-
icantly lower and serum inorganic phosphorus higher in the
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Table 3. Comparison of the initial chemistries (means sEM)
Normals(N=9) CRF(N=6)
CAPD
(N=7)
HD(N8)
Sodium mmo!/liter 140 0.4 138.8 1.0 140.6 0.5 138.4 1.0
Potassium mmol/liter 4.4 0.3 4.6 0.3 4.0 0.3 5.1 3°
Chloride rnmol/liter 102.1 0.4 104.2 1.2 97.4 0.9° 99.4 1.7
Bicarbonate mmol/liter 27.8 0.8 16.0 1.8° 24.3 0.8° 17.8 1.1°
BUN mmol/liter urea 5.9 0.6 30.4 34a 24.1 2.3° 28.4 1.6°
Creatinine ,ismol/liier 97 4 875 177° 1326 221° 1208 ioia
Glucose mmol//iter 4.6 0.2 6.3 1.3 5.9 0.6° 51 0.4
Acetate p.mol/!iter 29.3 6.8 28.4 4.6 26.2 5.4 258.5 180.6a
Calcium mmol/liter 2.27 0.3 1.95 0.12° 2.25 0.05 2.30 0.06
Phosphorus mmo!/liter 1.16 0.3 1.77 0.13° 1.94 0.16° 2.17 0.36a
Magnesium mmol/!iter 0.80 0.05 0.85 0.1 0.80 0.1 1.20 0.06
Alkaline phosphataset' U/liter
AST U/liter
72 4
17 1
122 10
14 3
89 15
33 5
156 50
33 laI
Albumin glliter 47 1 42 2° 37 2° 40 ia
P < 0.05 compared to normals
b Normal range 39—390 U/liter
Normal range 1—37 U/liter
d Above normal limits in one of eight subjects (108 U/liter)
three groups with CRF compared to normals. Serum albumin
was also significantly lower in those groups compared to
controls. Serum calcium was lower in non-dialyzed CRF pa-
tients and serum potassium, magnesium, acetate and AST
higher in HD patients.
Acute four hour and one week post-HD changes for both
acetate and acetate-free dialysate are shown in Table 4. Acute
changes in potassium, urea nitrogen, calcium, creatinine, and
albumin were of similar magnitude with either dialy sate. Higher
four hour post-dialysis bicarbonate, chloride, and phosphorus
levels occurred with acetate-free dialysate, compared to acetate
dialysate. The differences in bicarbonate and chloride reflect
the differences in dialysate concentrations of these anions.
Transforming growth factor /3
Platelet counts, platelet factor 4 (PF4), and /3-thromboglobu-
un levels, performed to detect in vivo and in vitro platelet
activation or destruction, are shown in Table 5. TGF/31 levels
for the four groups are shown in Figure 1. Median TGF/31 levels
were increased in the CRF (75 pg/mI; range 70 to 97) and CAPD
(75.5 pg/mI; range 66 to 116) groups compared to normals (57
pg/mi; range 53 to 68), P < 0.05. Although higher, TGF/31 levels
in I-ID subjects (median 68 pg/mI; range 52 to 88) were not
statistically different from normals. TGF/31 levels pre, four
hours post-, and one week post-HD with acetate versus acetate-
free dialysate are shown in Figures 2A and B. Platelet counts,
PF4, and /3-thromboglobulin levels for this acute study are
shown in Table 6. No changes in TGF/3 levels occurred during
acetate-free HD (68,5 pg/mI; range 62 to 97 vs. 70 pg/mI, range
52 to 86), but, uncorrected for UF, levels increased acutely four
hours after acetate HD (Fig. 2A) (70 pg/mI; range 63 to 88 vs.
79.5 pg/mI; range 65 to 140, P < 0.05). (A sample was not
obtained from one subject pre-acetate.) When corrected for
UF, TGFJ31 was higher after acetate HD than after acetate-free
HD (Fig. 2B) (68 pg/mI; range 51 to 115 vs. 57 pg/mI; range 43
to 69, P <0.05). After one week of acetate-free dialysis, TGF/3,
was lower than after acetate dialysis (Fig, 2A) (63 pg/mI; range
59 to 73 vs. 69 pg/mi; range 51 to 97), but two values were not
obtained after acetate and the difference did not reach statistical
significance,
Inflammatory cytokines
Results are shown in Table 7. In general IL-lf3, IL-la, IL-6,
TNFa, and IFNy were not consistently detected in any of the
groups including post-HD with either acetate or acetate-free
dialysate.
/32-micro globulin
As shown in Figure 3, /32-microglobulin levels were not
significantly different pre-HD, after four hours corrected and
uncorrected for UF, or one week post- for acetate and acetate-
free HD (85.2 g/ml 10.1 vs. 77.0 g/ml 8.1; 95.2 jzg/ml
7.3 vs. 89.1 g/ml 8.8; 81.2 g/ml 8.1 vs. 72.5 g/ml 6.9;
and 80.1 pg/mi 8.5 vs. 88.0 /.Lg/ml 11.4, respectively).
Levels after four hours increased for both acetate and acetate-
free HD, but not if corrected for UF.
Discussion
Both the apparent influence of acetate on TGFI31 and the
higher TGF/31 levels compared to controls found in all the
uremic groups are of interest. TGF/31 is a platelet peptide which
can induce responses characteristic of tissue repair or injury
[141. Dependent upon cell type [27], it has both stimulatory and
inhibitory effects. For example, TGF/31 inhibits cytokine pro-
duction by activated lymphocytes [13, 181, yet it is a potent
stimulant of mesenchymal cell growth and the transcription and
secretion by these cells of extracellular collagen and fibronectin
[15—171. In contrast, the inflammatory cytokines, IL-l and
TNFa, while also associated with stimulation of fibroblast
growth [61, appear to stimulate collagenase production [6, 28,
29] and to inhibit collagen secretion in the mesenchymal cells of
liver [30].
The TGFI31 plasma levels we found are within the range
previously reported for normal humans (65 pg/mI) when mea-
sured with an ELISA assay [24]. The PF4//3 thromboglobulin
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Table 4. Initial, 4 hour, and I week chemistries for acetate vs. acetate free HD (means sEM)
Acetate (N = 8) Acetate-free (N = 8)
Pre- 4 hr I week Pre- 4 hr 1 week"
Sodium 137.4 0.07 137.4 1.0 137.7 0.5 138.6 0.8 139.0 0.4 136.8 0.8
mmol/liter
Potassium 5.1 0.3 3.4 0.la 5.1 0.3 5.1 0.3 3.6 0.Ia 4.9 0.3
mmollliter
Chloride 98.8 1.4 96.6 1.2 98.1 1.3 99.1 1.7 100.8 0.5" 98.0 1.2
mmol/liter
Bicarbonate 18.6 1.1 20.1 0.9 19.6 1.2 18.6 1.3 23.8 06a,b 18.6 0.8
mmol/liter
BUN 27.0 1.8 10.1 l.oa 28.5 5.5 26.5 2.0 9.9 0.9a 26.2 2.0
mmol/liter urea
Creatinine 1193 98 557 44 1167 106 1220 106 522 53 1167 88
mol/liter
Glucose 5.2 0.3 5.6 0.3 5.4 0.3 5.5 0.3 5.8 0.4 5.4 0.3
minol/liter
Acetate 46.9 7.7 1921 1212 60.9 10.8 267.0 174.0c 66.2 15.5 57.5 10.1
jimol/liter
Calcium 2.32 0.05 2.79 0.05a 2.35 0.07 2.30 0.07 2.69 0.03a 2.27 0.07
mmol/liter
Phosphorus 1.87 0.06 0.87 OlGa 2.20 0.26 2.22 0.32 1.05 O.O7.b 1.97 0.29
mmol/liter
CaxP product
(mg/dl)2
53.5 7.7 29.8 3.1 63.3 7.4 62.9 9.1c 35.3 2.7a 56.6 9.5
Magnesium 1.20 0.05 1.15 0.05 1.29 0.06 1.22 0.06 1.15 0.OSa 1.18 0.06
mmol/liter
Alkaline phosphatase 156 50 176 57 119 32 161 51 178 59 158 51
U/liter
AST 33 11 27 2 33 II 33 10 37 12 28 7
U/liter
Albumin 40 1 45 2 40 1 40 1 44 ia 40 I
g/liter
a P < 0.05 compared to pre-HD
b P < 0.05 compared to post-4 hr acetate D
P < 0.05 compared to pre-acetate D
d N = 7; one subject not tested at one week
Normals(N=9) CRF(N=6) CAPD(N=7) HD(N=8)
Platelets 305 23 251 9 313 54 209 l8
109/liter
PF4 47.7 72 22.2 6.l 30.5 7.3 22.6 5.o
ng/ml
/3-TG 57.5 4.8 61.4 13.6 58.1 7.6 85.5 12.3
ng/ml
j3-TG/PF4 1.3 0.07 2.9 7 2.5 0.5 4.3 o.7
ratios indicate that in vitro platelet activation was not a signif-
icant source of TGF/3, [25], but the influence of both platelet
counts and decreased GFR on these platelet proteins is uncer-
tain [25]. Since there was no change in platelet counts during
HD, in vivo destruction resulting in TGF/3, release is not likely
to have occurred. Together, these suggest that the changes in
TGFI31 levels during dialysis are not due to method artifacts.
Important in the context of acetate administration to hemo-
dialysis patients is the observation that TGFJ3 is an early and
potent inducer of the expression of platelet-derived growth
factor (PDGF) [19]. PDGF, a 26 dK peptide with a B chain
homologous to the C-sis oncogene, is found primarily in plate-
Normal CRF CAPD HD
Fig. 1. TGF/31 levels in the four groups: normals N = 8; CRFN = 6;
CAPDN = 6; HD N = 8. Levels for HD patients were measured prior
to the first dialysis of the acute study. Results below detection limit are
shown as 0 pg/mI.
lets and monocytes [31]. This growth factor may be significant
in the pathogenesis of atherosclerosis [11] and idiopathic pul-
monary fibrosis [32]. In the latter case it is produced by
activated macrophages. Recent reports suggest that PDGF
Table 5. Platelets, counts, PF4, and 13-thromboglobulin levels
(means SEM)
a P < 0.05 compared to normals
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Table 6. Initial, 4 hr, and I week platelet Counts , PF4, and /3-thromboglobuun levels for acetate vs. acetate-free HD (means sFM)
Acetate (N = 8) Acetate-free (N 8)
Pre- 4 hr 1 weekaPre- 4 hr I week
Platelets 229 19 241 24 215 18 210 18 218 15 225 13
109/liter
PF4 18.2 1.8 37.6 5•9b 26.3 24b 24.6 5.0 25.7 2.6 16.8 2.8
ng/ml
/3-TG 68.2 8.7 87.1 67b 106.0 15.1 112.1 15.6 67.7 14•7d 68.2 7,9e
ng/ml
/3-TG/PF4 3.9 0.4 2.7 0.5 4.4 0.9 5.4 0.9 3.5 1.2 4.5 0.6
N = 7; one subject not studiedb P < 0.05 compared to pre-acetate HD
c p < 0.05 compared to post-I week acetate HD
d One not obtained
P < 0.05 compared to pre-acetate-free HD
activity, measured by bioassay on muscle cells, is increased in
the plasma of patients undergoing hemodialysis [12]. Although
technical problems with the assay prevented PDGF measure-
ment in this study, the interrelationship between acetate,
TGF/3, and PDGF requires further study. If it can be shown that
acetate does effect PDGF either directly or via TGF/31, this may
have implications for ectopic vascular calcification since ace-
tate may also alter Ca/P kinetics during HD. The lower inor-
ganic phosphorus we found four hours after acetate HD com-
pared to acetate-free HD may, in fact, be consistent with
intracellular movement of phosphate as a result of acetate
metabolism [2]. Calcium and magnesium pyrophosphate accu-
mulation in mitochondria could then result [331. Clinically,
patients with an elevated calcium phosphate product (70) are
at risk of tumorous soft tissue calcification and possibly vascu-
lar calcification [34], so, although neither were statistically
significant, the improved inorganic phosphorus and calcium
phosphate product after one week of acetate-free dialysate
compared to the deterioration after one week of acetate dialy-
sate may also be important. Magnesium is also found in soft
tissue calcifications, although more so in visceral than vascular
tissue [351. The higher magnesium levels of the commercial HD
versus CAPD dialysate we employed reflect the different opin-
ions of the effect of dialysate magnesium both on renal bone
disease and soft tissue calcifications. Dialysate magnesium
concentrations of 0.25 mr'i have been advocated for both HD
[36] and CAPD [37]. Low magnesium dialysate, for example,
may improve renal bone disease without measurable effect on
serum PTH [38, 39], yet others have reported less vascular
calcification during HD with 0.75 m magnesium dialysate [401.
A
1114 Anderson et a!: Acetate dialysate effect on TGFI32, IL-I and /32m levels
.
150
125
100
75
50
25
0
150
125
100
75
50
25
—
BELOW DETECTION LIMIT
-
.
0
B
Fig. 2. A. TGFI3 levels at 0 hr, four hr
(uncorrected for UF), and 1 week for acetate
versus acetate-free HD (N = 8). One subject
tested only after 4 hr acetate HD. One subject
not tested after one week of acetate-free HD.
B. TGF/3 levels at 0 hr and 4 hr (corrected for
UF) by the formula of Bergstrom [26]. Range
___________________________________________________________________________
below detection limit is not shown because
Pre 4hr lwk Pre 4hr lwk values are calculated from values above thelimit. One subject tested only after 4 hr
Acetate Acetate-free acetate HD.
Corrected for UF
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Table 7. Number of subjects with detectable cytokines or interferon
gamma
Normals CRF CAPD HD(N=9) (N=6) (N=7) (N=8)
IL-ia 2b c 1d ie
IL-1/3 0 0 0 0
IL-6 0 0 0 0
TNFa 0 i i 4g
INFy 1h 0 3J
a All HD patients had cytokines and interferon measured pre-HD, 4
hr post-HD, and post-i week HD for both acetate and acetate free HDb 138 and 8.8 pg/mi; DL 5 pg/mi
82 pg/mId 55 pg/mI
e Detected in one subject pre- (181 pg/mI) and post- (129 pg/mi)
acetate HD
23 pg/mi
g Detected pre-HD in 4 subjects (21 pg/mI, 26 pg/mI, 15 pg/mi, i8
pg/mi, DL 10 pg/mi); not detected post-dialysis or during other dialysesh 5 U/mi; DL 5 U/mI
6.8 U/mI
Detected pre- and post-acetate (13 U/mi, 6 U/mi), and post-acetate-
free (iI.3 U/mi) in one patient; post-acetate (5 U/mi) in one patient;
pre-acetate (6.8 U/mI) in one patient
Finally, although peritoneal dialysis exposes patients to lactate,
not acetate, CAPD patients had even higher TGF/31 ievels, and
phosphorus kinetics are likely also altered by lactate metabo-
lism.
Whether TGFI3 is primarily increased in patients with chronic
renal failure or increased secondary to decreased clearance
cannot be determined from this study. Nonetheless TGF/3 may
be important in the progression of CRF. Giomerular cell prolif-
eration and accumulation of mesangiai matrix material appear
to be important findings in several progressive glomerular
diseases [41, 42]. TGF/3 is present in both mouse renal tubules
[43] and rat glomeruli [44], and TGF/3 receptors have been
found in rat glomeruli [45, 46]. MacKay et al [45] have found
complex effects of TGF/31 on glomerular endothelial, epithelial
and mesangial cells: endotheiial and epithelial cell proliferation
is inhibited and epidermal growth factor (EGF), insulin-like
growth factor (IGP-l), and PDGF stimulation of DNA synthesis
diminished; sparsely-plated mesangial cell proliferation to fetal
bovine serum, EGF, IGF-i, and PDGF is diminished but
densely-plated mesangial cell proliferation stimulated. In addi-
tion, TGFJ3 stimulates collagen, fibronectin, and proteoglycan
production in mesangial cell cultures [43, 47], and the produc-
tion of fibronectin by glomerular epithelial cells [43]. Thus, it
has been suggested that TGFJ3 may play a substantial role in the
regulation of processes which appear critical to the initiation of
progressive glomerular diseases [47, 481. Whether circulating
levels of TGFj3 reflect these actions in the kidney is not known.
The role, if any, of TGF/3 in renal bone disease remains
unexplored. Apart from platelets, bone also contains large
amounts of TGF/3 [13], and it may play an important role in
bone formation [20].
Our inability to detect IL-ia, IL-1f3, or TNFa with ELISA
assays in the serum of most non-dialyzed uremics, CAPD, or
HD patients or find acute increases of these cytokines after HD
with either acetate or acetate-free dialysate differs from the
findings of Herbeiin et a! [5], but agrees with others who found
that IL-I is not detectable with ELISA assays [49]. Using the
same ELISA assay as we did, Herbelin reported elevated IL-1/3
levels pre-HD (31.15 pg/mi 5.05 SEM) and acute increases
post-HD (51.15 pg/mi 12.70 SEM) in long-term dialysis pa-
tients, values which were described as "much lower" than
found in renal ailograft recipients [501. Because they could not
detect IL-1f3 in uremics pre- or post- their very first dialyses,
they suggested that IL-lf3 production may be dependent on the
duration of dialysis treatment. Our subjects, however, had been
on HD for a similar duration so this cannot explain our differing
results. They employed acetate baths for nearly all their sub-
jects and found no differences between the use of polyacriloni-
true or celluiosic membranes such as we used. They did not
state the length of each dialysis, a factor which, if different than
the four hours we used, might affect post-HD IL-l/3 levels.
They did, however, employ gel filtration of plasma prior to
measuring IL-i levels in order to remove proposed inhibitory
factors [51]; it is unlikely that such inhibitors would effect an
ELISA assay. Neither that study nor ours measured endotoxin
contamination directly, but the absence of increased TNFs
levels in most of our subjects is indirect evidence against
significiant contamination since TNFa production is easily
stimulated by endotoxin [52].
We also could not confirm the consistent elevations of TNFa
in predialysis uremics Heberlin et at found with an ELISA
assay [5]. Results similar to ours were found with a bioassay in
a study of TNFa levels in congestive heart failure which
included uremic controls [53]. Elevations of TNFa have been
found in our laboratory with this assay, however, in patients
with alcoholic hepatitis [54]. It should be noted that the slight
but statistically significant AST elevation found initially in our
HD group was the result of a single subject with transient
transaminase elevations of unknown etiology. That subject's
cytokine levels were not different from the other subjects.
Given the absence of detectable serum IL-la, IL-1$ and
TNFa after either acetate or acetate-free dialysate, we cannot
confirm that acetate causes monocyte activation as found by
Bingel et at [9] in vitro. There is, however, evidence of
increased interleukin production in some [55, 56], but not all
[57], in vitro studies of monocytes cultured on or brought into
contact with dialysis membranes, of increased post-dialysis
cellular IL-I production found when monocytes are harvested
from patients after hemo- or peritoneal dialysis [58, 591, and of
increased serum cytokine levels measured with the thymocyte
coproliferation bioassay after hemodialysis [3—5]. The latter
bioassay is not specific for IL-I [60, 61] and it is not known if it
or the ELISA assay is more sensitive in uremics, as only the
Heberlin study measured IL-i with both assays. We believe
further studies are required to evaluate the usefulness of ELISA
assays of serum cytokine levels as measures of monocyte
activation during dialysis. The ELISA assays we employed may
not be sensitive enough, or the half life of cytokines induced by
diaiysis may be too short to have been detected in a study of
this type. As has been suggested, determination of increased
cytokine production may require assessment of intracellular
generation, membrane binding, and dialysate loss [60]. More
importantly, studies need to be performed which establish a
causal link between the occurrence of monocyte activation and
the proposed end organ effects of these cytokines in dialysis
patients.
Finally, we confirm the findings of others that, provided
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correction for ultrafiltration is made, /32-microglobulin levels
are not increased after HD even with cuprophan membranes
126], nor did we find any evidence of adverse effects of acetate
dialysate on /32-microglobulin levels.
In conclusion, in this study we could not consistently detect
IL-la, IL-1f3, IL-6 versus TNFa in either pre-dialysis uremics,
CAPD patients, or HD patients either pre- or post-dialysis. Use
of ELISA assays may be problematic for detection of these
cytokines without measuring cellular production membrane
binding or dialysate loss. We did, however, detect increased
TGF/31 in non-dialyzed uremics, CAPD patients, and after
acetate hemodialysis. This finding may have implications both
for the progression of chronic renal disease and the vascular,
immunologic, and bone metabolism complications that occur in
both chronic uremic and dialysis patients. Finally, we found no
adverse effects of acetate HD on f32-microglobulin levels.
Reprint requests to.J. Anderson, M.D., Renal Division, Francis Scott
Key Medical Center, 4940 Eastern Avenue, B2N, Baltimore, MD 21224,
USA.
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